Skip to main content

Seattle Structural Genomics Center for Infectious Diseases – Year XVI


EMSL Project ID
60832

Abstract

The rapid spread of SARS-CoV-2 through-out the world and its life-changing impact on the day-to-day lives of Americans punctuate the need to be ever cautious of the emergence of new epidemic infectious diseases. COVID-19, along with the expansion of multi-drug resistant strains of infectious agents, makes developing new drugs to combat emerging and re-emerging infectious diseases of upmost importance. Even with the arrival of AlphaFold, a program that predicts protein structures well, the National Institute of Allergy and Infectious Diseases (NIAID) continues to expand a library of experimentally verified, three-dimensional protein structures of potential drug targets that may be used for the structure-based design of new drugs. Towards populating this library NIAID has established two structural genomics centers: The Center for Structural Genomics of Infectious Disease (CSGID) and the Seattle Structural Genomics Center for Infectious Disease (SSGCID). The high-field suite of NMR spectrometers at EMSL will assist the population of the structure library through the high-field NMR data used to determine the solution structures of proteins identified as potential drug targets. In addition to solving structures, NMR spectroscopy will also be used for a variety of NMR-based experiments to better understand the function of infectious disease drug targets (eg: dynamic studies, chemical shift perturbation studies (Buchko et al., 1999), enzyme kinetic measurements, and ligand screening).

Project Details

Start Date
2023-04-28
End Date
2023-09-30
Status
Closed

Team

Principal Investigator

Garry Buchko
Institution
Pacific Northwest National Laboratory